These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 11219567)

  • 1. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
    Reust CE
    J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
    [No Abstract]   [Full Text] [Related]  

  • 2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
    Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
    Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML; Berger BM; Farber FL
    Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
    Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
    East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A reply on cervix cancer screening: cervical cytological test doesn't fulfil the requirements of a good screening test].
    Bistoletti P
    Lakartidningen; 2000 Sep; 97(37):4042. PubMed ID: 11036367
    [No Abstract]   [Full Text] [Related]  

  • 7. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Levin CE; Sellors JW
    Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving the sensitivity of cervical cytology: what are the issues?
    Myers ER
    Am J Manag Care; 2000 Jul; 6(7):838-40. PubMed ID: 11067380
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public expectations, achievable cervical screening sensitivity, and the standard of practice.
    Austin RM
    Cancer; 2003 Feb; 99(1):1-3. PubMed ID: 12589638
    [No Abstract]   [Full Text] [Related]  

  • 11. [Population screening for uterine cervix cancer: the negative effects of insufficient knowledge as to what is normal and abnormal].
    van der Graaf Y
    Ned Tijdschr Geneeskd; 2002 Aug; 146(34):1569-71. PubMed ID: 12224477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of population screening and rescreening for cervical cancer in the Netherlands.
    Boon ME; de Graaff Guilloud JC
    Acta Cytol; 1981; 25(5):539-42. PubMed ID: 6792845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
    Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
    J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does cervical cancer screening do more harm than good?
    Payne L; Lavis P
    Nurs Times; 2001 Jul 19-25; 97(29):20. PubMed ID: 11957496
    [No Abstract]   [Full Text] [Related]  

  • 17. New tests for cervical cancer screening.
    Nuovo J; Melnikow J; Howell LP
    Am Fam Physician; 2001 Sep; 64(5):780-6. PubMed ID: 11563569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial].
    Bistoletti P; Ellström A; Dillner J; Sennfält K; Sparén P; Strander B
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1874-6, 1878-9. PubMed ID: 16044766
    [No Abstract]   [Full Text] [Related]  

  • 19. A decade has passed...the Pap smear and cervical cancer.
    Linder J
    Am J Clin Pathol; 1997 Nov; 108(5):492-8. PubMed ID: 9353086
    [No Abstract]   [Full Text] [Related]  

  • 20. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.